Altano – Partnership with Equine Clinic Grosswallstad

January 2018

Partners and Friends of Ufenau Capital Partners, we are delighted to announce,that Ufenau portfolio company Altano Gruppe GmbH(“Altano”) has acquired Equine Clinic Grosswallstadt(“Pferdeklinik Grosswallstadt”) and therewith expands its geographical footprint in Germany.

The Equine Clinic Grosswallstadt is a leading regional Champion specializing in equine medical diagnostics and surgery. The 53 highly qualified employees including the two renowned vets Holger Fischer and Souel Maleh treat around 6,000 patients each year. The Equine Clinic has an outstanding reputation in surgery, equine dentistry, regenerative equine medicine including stem cell therapies as well as sports medicine in addition to the general, horse-medical treatment and therapy offer.

In addition, the clinic owns a physical therapy centre for post medical treatments. Dr. Holger Fischer, CEO of the Grosswallstadt Equine Clinic: “With Ufenau and Altano, we have found a partner who, at eye level, has a good understanding of the market in order to improveour equine clinic sustainably.”

Dr. Victor Baltus, CEO of Altano, adds: “This third acquisition within 6 months is another important step in strengthening the regional presence of Altano in the greater Rhine-Main area.

We are delighted that we have found such a great partner with the Equine Clinic Grosswallstadt.”

Yours sincerely,

the Ufenau Team

 

 

About Ufenau Capital Partners

Ufenau Capital Partners is a privately owned Swiss Investor Group headquartered at the Lake Zurich which advises private investors, family offices and institutional investors with their investments in private equity. Ufenau Capital Partners is focused on investments in service companies in German-speaking Europe and invests in the Education & Lifestyle, Business Services, Healthcare and Financial Services sectors. Through a renowned Group of experienced Industry Partners (Owners, CEOs, CFOs), Ufenau Capital Partners pursues an active value-adding investment approach on eye-level with entrepreneurs and managers.

 

Categories: News

Tags:

Oncgnostics reaches the funding limit on seedmatch of € 750,000 early

BM-T

Oncgnostics GmbH has reached the funding limit of € 750,000 on the crowdfunding platform seedmatch 39 days before the end of the campaign. The first funding threshold of € 100,000 was already reported 2.5 hours after the start of the seedmatch campaign on 14 December 2017.

The company is a spin-off of the Gynecological Clinic of the University of Jena and develops – based on patented epigenetic markers – highly reliable molecular biology tests for early diagnosis, treatment decision and follow-up in cancer diagnostics.

With the raised crowd investment, oncgnostics will promote the positioning and marketing of the product GynTect® in the European and North American markets. Additionally further studies will be performed to reach a broad acceptance of GynTect® with the health insurance companies.

http://www.oncgnostics.com/?lang=en

 

Categories: News

Tags:

Apax Digital leads $60 million funding round in SoYoung

Apax Digital

Apax Digital’s backing of China’s leading online marketplace for aesthetic medical treatments is the Fund’s second investment 

New York and London, 3 January 2018 – Apax Digital (“the Fund”) has today announced that it has led the $60 million Series D funding round in SoYoung, the largest online marketplace for aesthetic medical treatments in China. Through SoYoung’s native app and websites, customers can research aesthetic medical treatments, doctors, and clinics, and can directly book procedures with participating providers. Apax Digital was joined in the funding round alongside new and existing investors.

The Chinese aesthetic medicine market is large and growing, driven by favourable socio-economic, demographic, and cultural trends. Against this backdrop, SoYoung, founded in 2013 and headquartered in Beijing, has experienced impressive growth and market share gains, driven by its strong value proposition connecting consumers and providers. The new funding will be used to continue to drive marketplace improvements, geographic expansion, and customer acquisition.

Jin Xing, CEO of SoYoung, said: “We are delighted to welcome Apax Digital as a partner and investor in our business. Apax Partners’ extensive track record in digital marketplaces, experience in healthcare investment, leading Chinese market presence, and proven operating team made it the ideal partner for our business as we continue to bring our app and services to a greater number of consumers. We look forward to working with Apax Digital as we move into the next phase of our growth.”

Marcelo Gigliani, Managing Partner of the Apax Digital team, said: “We have been very impressed with the strong value that SoYoung brings to both consumers and clinics, and with the company’s world-class traffic growth, engagement, and monetization model. We are eager to leverage our experience investing in digital marketplace businesses by partnering with Jin Xing and his team to continue SoYoung’s market leadership expansion over its next exciting growth phase.”

Richard Zhang, Partner and Head of Apax Greater China, said: “Apax Partners has long been actively involved in the Chinese market. With the completion of SoYoung, Funds advised by Apax Partners (“the Apax Funds”) have invested c.$400m in China during 2017. We are very pleased to work alongside Apax Digital with this investment; SoYoung is a leading player in a market with huge growth potential.”

The investment in SoYoung constitutes the eighth digital marketplace investment by the Apax Funds. Prior recent digital marketplace investments include Auto Trader (UK), Boats Group (US), idealista (Spain), SouFun (China), and Trader Corporation (Canada).

The investment also follows the announcements last month of Apax Digital’s successful raising of its $1 billion fund, which reached its hard cap, and its first investment – in Moda Operandi, a leading, multi-brand luxury ecommerce business known for selling runway apparel on an exclusive basis.

About Apax Digital
Apax Digital is a $1 billion fund raised in 2017 focused on minority and buyout investments in high-growth enterprise technology and internet companies globally.  Advised by Apax Partners, a global private equity firm, Apax Digital’s investments are focused on subsectors where Apax Partners has expertise, including vertical software, data & analytics, tech-enabled services, marketplaces, digital media, and disruptive e-commerce. For further information about Apax Digital, please visit http://digital.apax.com.

Over its more than 35-year history, Apax Partners has raised and advised funds with aggregate commitments of $51 billion*. These funds provide long-term equity financing to build and strengthen world-class companies. For further information about Apax Partners, please visit http://apax.com.

* Funds raised since 1981, commitments converted from fund currency to USD at FX rates as at 30 September 2017.

About SoYoung
Founded in 2013, SoYoung is the largest Chinese online medical aesthetic marketplace, allowing in-market consumers to research treatments, clinics, and providers, and book services directly through its proprietary platforms. The Company is a community-driven lead generation marketplace, comprised of user-generated reviews, rankings, videos, and other info about medical aesthetic treatments, doctors, and hospitals. For further information about SoYoung, please visit http://soyoung.com.

Media Contacts 

Apax Partners LLP – Global media inquiries
Andrew Kenny, Head of Communications
Tel: +44 20 7872 6371
Email: andrew.kenny@apax.com

Apax Partners LLP – NorAm and LatAm media inquiries
Todd Fogarty
Tel: +1 212 521 4854
Email: todd.fogarty@kekst.com

Apax Partners LLP – EMEA media inquiries
Greenbrook Communications
James Madsen, Matthew Goodman, Annabel Clay
Tel: +44 20 7952 2000
Email: apax@greenbrookpr.com

SoYoung – Media inquiries
Mo Lv
Tel:  +86 10 5707 6564
Email: marketing@soyoung.com

Categories: News

Tags:

Almi Invest invests in gedea Biotech

Almi Invest

Almi Invest invests two million in gedea Biotech, which is developing a new treatment for vaginal infections. In the issue of a total of 11 million is also participating private investors. The money will go to clinically validate the treatment method.

In 2018, the company, which is based in Lund, Sweden, to carry out a clinical study for the treatment and prevention of vaginal yeast infection.

Many women suffer from repeated vaginal infections without being cured. Gedea Biotech active substance acts in a new way by the fungus usually located behind loses its infectivity while other fungi and bacteria is inhibited by the substance pH-lowering properties.

The substance is naturally occurring and is also approved as a food additive and its effect gives great hopes for an effective and safe treatment that does not contribute to the emergence of antibiotic resistance.

– gedea has an interesting solution with high medical value that are able to quickly and cost-effectively get to the proof-of-concept and market, says Per Antonsson, Investment Manager at Almi Invest.

Among the investors in the issue is the investment company Porte-Monnaie, which primarily invests in unlisted companies. The company was founded in 2013 by Joakim Falk, Pouyan Kasraian and Staffan Gestrelius.

– It is gratifying that we have now established cooperation with knowledgeable and committed investors. They have great skills in general construction, sales and marketing of this type of products, says Annette Säfholm, president of gedea Biotech.

 

Categories: News

Tags:

Nordstjernan to invest in Mama Mia

logo

Nordstjernan is expanding in the health and medical care sector by acquiring a majority of the shares in Barnmorskegruppen MAMA MIA Aktiebolag (“Mama Mia”) as an add-on acquisition for Lideta Hälsovård (“Lideta”). The sellers, the Wahlström family, will become partners in the company that will consist of both Lideta’s and Mama Mia’s operations. The current CEO of Lideta, Hugo Lewné, will continue as CEO of the group. At the same time, Mama Mia’s CEO Eva Laurin will become part of Lideta’s management team.

Mama Mia provides maternity and child health care services at seven clinics in Stockholm and Malmö, and primary health care at two clinics in Stockholm under the brand To Care. The company, founded in 1988 by Christina Wahlström, has grown rapidly over the last few years and with a little over 170 employees, its annual sales for the previous fiscal year were just under SEK 200 million. With this acquisition, Lideta is strengthening its position in maternity and child health care services, as well as in primary health care.

Tomas Billing, CEO of Nordstjernan, says:
“We look very positive at Mama Mia’s business and brand. Nordstjernan’s ambition is to develop a high-quality company in Swedish health and medical care over several years.”

Eva Laurin, CEO of Mama Mia, says:
“We are very pleased to have Nordstjernan as majority shareholder in Mama Mia. Our family looks forward to continuing to develop the company together with Nordstjernan and Lideta.”

The parties have agreed not to publish the terms of the transaction.

Tomas Billing
President and CEO
Nordstjernan AB

Questions will be answered by:

Tomas Billing, CEO, Nordstjernan
Telephone: +46 8 788 50 18
E-mail: tomas.billing@nordstjernan.se

Hugo Lewné, CEO, Lideta Hälsovård
Telephone: +46 42 453 04 90
E-mail: hugo@lideta.se

Eva Laurin, CEO, Mama Mia
Telephone: + 46 707 70 00 29
E-mail: eva.laurin@mamamia.se

Nordstjernan is a family-controlled investment company that creates growth in value through long-term and active ownership of Nordic companies. More information about Nordstjernan is available at www.nordstjernan.se 

Lideta Hälsovård is a medical care company that engages in primary care in Stockholm and southern Sweden. More information about Lideta is available at www.lideta.se 

Mama Mia provides maternity health care, child health care, and primary health care services in Stockholm and Malmö. More information about Mama Mia is available at www.mamamia.se


 

 

Categories: News

Tags:

Ecolab agrees to acquire minority ownership in Finnish MetGen

Tesi

Ecolab Inc., the global leader in water, hygiene and energy technologies and services has acquired a minority stake in MetGen OY. As part of the acquisition, Ecolab will be granted exclusive distribution rights globally for MetGen’s pulp and paper portfolio, as well as its wastewater enzyme portfolio. This business supplies differentiated custom blended enzymatic solutions to maximize biomass performance for various industries.

MetGen, headquartered in Kaarina, Finland, designs novel enzymatic solutions to improve energy efficiency and speed of processes in industries such as Pulp and Paper, Biofuels and Biochemicals.

“We are glad to welcome Ecolab as an investor in MetGen. Our business goals are fully aligned with Ecolab’s objective to support customers to achieve the best solutions in water technologies for the pulp and paper sector.  MetGen is excited to work together with the Ecolab team to accelerate market growth through the global introduction of innovative, sustainable enzymatic solutions in various business segments,” said Alex Michine, CEO of MetGen.

The investment provides Ecolab with access to innovative custom enzymes to help producers improve machine efficiency, water and energy savings, product quality and profitability. The terms of the transaction were not disclosed.

“We are excited to work with MetGen and implement their innovative products into our offerings to enhance Ecolab’s ability to provide value-added solutions for our customers in the Pulp and Paper Industry,” said Jerome Charton, senior vice president and general manager, Nalco Water global paper, Ecolab’s water management business.


For more information, please contact:

Alex Michine, CEO, MetGen Oy, +358 40 543 3740
skype: alexmichine
www.metgen.com

 

About MetGen Oy
MetGen designs and markets novel enzymatic solutions for the most challenging of industrial conditions to address our customer’s specific challenges. MetGen’s enzymes – MetZyme® – are industrial, highly-active, natural catalysts that accelerate chemical reactions and company uses advances in genetic engineering and microbiology to adapt enzymes to harsh industrial conditions and to handle a variety of lignocellulosic substrates. MetGen aims to be a widely recognized supplier of industrial enzymes, significantly contributing to the economics and sustainability of process industries such as pulp & paper, biofuels and biochemicals. MetGen’s competitive advantage is in tailoring or adapting enzymes to meet customer’s specific needs. www.metgen.com

About Ecolab
A trusted partner at more than one million customer locations, Ecolab (ECL) is the global leader in water, hygiene and energy technologies and services that protect people and vital resources. With 2016 sales of $13 billion and 48,000 associates, Ecolab delivers comprehensive solutions and on-site service to promote safe food, maintain clean environments, optimize water and energy use, and improve operational efficiencies for customers in the food, healthcare, energy, hospitality and industrial markets in more than 170 countries around the world. Follow us on Twitter @ecolab, Facebook at facebook.com/ecolab, LinkedIn at Ecolab or Instagram at Ecolab Inc.

About Tesi
Tesi (Finnish Industry Investment Ltd) is a venture capital and private equity company that accelerates companies’ success stories by investing in them directly and via funds. Tesi always invests together with other investors, providing them with access to high quality deal-flow in Finland. Our investments under management total 1 billion euros and we have altogether 723 companies in portfolio.
www.tesi.fi / @TesiFII

Categories: News

Tags:

ZytoService reaches an agreement to acquire Profusio

ik-investment-partners

ZytoService, a leading compounder of pharmaceuticals for patient-individualised infusions, has reached an agreement with GHD GesundHeits GmbH to acquire Profusio, the second largest compounder of cytostatics in Germany. Financial terms of the transaction were not disclosed.

Founded in 2002, ZytoService is one of the largest industrially organised §13 AMG (“Arzneimittelgesetz”) certified compounders for patient-individualised infusions applied mainly in oncology treatment in Germany. The company is based in Hamburg, where it runs a state-of-the-art compounding facility.

Profusio, a subsidiary of GHD, is the second largest cytostatics compounder in Germany with state-of-the-art manufacturing facilities in Leipzig, Haan and Munich.

“Profusio’s facilities are very well-invested, and they share our high standards of quality, safety, and professional expertise. Together, we will work towards our vision to create an integrated healthcare provider in the German oncology market,” said Enno Scheel, Co-Founder of ZytoService.

“The acquisition of Profusio will strengthen ZytoService’s market position and national footprint, giving us even better opportunities to address the growing demands of the German healthcare market,” continued Thomas Boner, Co-Founder of ZytoService.

ZytoService is owned by the IK VIII Fund, which is advised by IK Investment Partners. Completion of the transaction is subject to customary legal and regulatory approvals.

For further questions:

ZytoService
Thomas Boner, Co-Founder and Co-CEO
Phone: +49 40 600 094 013

Enno Scheel, Co-Founder and Co-CEO
Phone: +49 40 600 094 01

About ZytoService
ZytoService was founded in Hamburg in 2002. ZytoService now employs more than 470 highly-qualified personnel who have undergone pharmaceutical training. All staff are specially trained in GMP-compliant production. With more than 40 licensed pharmacists, ZytoService has outstanding expertise in all areas of oncological pharmacy. For more information, visit www.zytoservice.de

 

Categories: News

Tags:

Atlas-backed I-O specialist Kyn comes out of stealth mode

Atlas Venture

The immuno-oncology sector has yet another player. Kyn Therapeutics just made its debut after almost two years of gestation at Atlas Venture with three immuno-metabolism platforms and $49 million in first-round funding.

Explaining the rationale behind the new company, CEO Mark Manfredi told us that “the dramatic successes of checkpoint inhibitors have made their deficiencies and opportunities for improvement a hot topic in the industry, and a major driver for investment.”

“We believe immuno-metabolism is the next big area for immuno-oncology therapeutics, as it has the potential to generate broad-spectrum immune stimulation either alone or in combination with checkpoint inhibitors.”

Kyn comes out of stealth mode with a pair of preclinical programs targeting the kynurenine pathway, which is implicated in a number of diseases including cancer, as well as ARY-007, a prostaglandin E2 (EP4) receptor antagonist licensed from Japan’s AskAt Inc. that will be developed alongside affiliate company Arrys Therapeutics.

ARY-007 has already been through human trials outside of cancer and will be Kyn’s first clinical candidate, starting phase 1b trials next year, said Manfredi. The company has a big-hitting rival for the program, however, as Bristol-Myers Squibb has just licensed an EP4 receptor antagonist from longtime immuno-oncology partner Ono Pharma for $40 million upfront.

“The literature has increasingly evidenced a broad-ranging immunosuppressive function for this receptor, through multiple cellular mechanisms,” said the CEO. “Once we understood this, it was an obvious choice to assess in the cancer immunotherapy setting.”

Kyn’s kynurenine pathway candidates are further back in development but have “substantial” preclinical data showing they can improve anti-tumor immune responses, according to Manfredi.

The first focuses on Kynase—an enzyme that degrades kynurenine directly and addresses both IDO (indoleamine 2,3-dioxygenase) and TDO (tryptophan 2,3-dioxygenase) immunosuppression pathways—and grew out of work the University of Texas at Austin.

There’s no shortage of other groups working on IDO—with BMS, Incyte and NewLink currently leading the charge—but fewer have focused on TDO. Kyn’s approach of targeting Kynase may lead to “efficacy in tumors that overexpress either IDO, TDO or both [and] therefore … could address a broader patient population than IDO inhibitors alone,” according to Manfredi. Added to that, its candidates seem to be much stronger at blocking kynurenine than IDO inhibitors in clinical trials.

The third pillar of Kyn’s portfolio is an in-house program geared towards developing aryl hydrocarbon receptor (AHR) antagonists that aim to block immunosuppression activated by various metabolites, including kynurenine.

The IDO/TDO and AHR programs are closely linked. In cancer cells, IDO and TDO stimulate the formation of kynurenine, which in turn activates AHR receptors and leads to an increase in immunosuppressive T cells in the tumor microenvironment. Moreover, AHR can also be activated by ligands other than kynurenine.

“In terms of clinical development, immunometabolism-based therapies are the next most advanced area within immuno-oncology,” he said, adding, “We think there is a lot of potential for our candidates in multiple solid tumors, but we’re not ready yet to talk specifics.”

“We also have a potential aid to efficiency in that the pathways we are exploring have several biomarkers—including the target metabolites themselves—that could lend themselves to patient enrichment approaches to study design.”

The $49 million in series A funding from Atlas and OrbiMed will be split two ways, with Arrys allocated $21 million for the EP4 project—which is subcontracted to Kyn—and the remaining $28 million going to the IDO/TDO and AHR programs, which should have lead development candidates selected in the next 12 to 18 months.

“We expect to add about 5 to 8 new employees internally over the next 12 months,” Manfredi told us. “Several of those employees will focus on candidate optimization and preclinical studies but we will also grow our internal clinical program management expertise.”

Categories: News

Tags:

HTL-Strefa strengthens Board of Directors with Rick Cook

eqt

HTL-Strefa is a fast-growing global med-tech company and pioneer in the medical sharps’ industry. The company is going through an exciting phase – transforming its commercial profile and execution capabilities, which has led to higher demand from customers. In order to fulfill the increased demand and to support the implementation of new investments in production, Rick Cook, former Global Head of Operations at Becton Dickinson, will join HTL-Strefa’s Board of Directors.

EQT V portfolio company HTL-Strefa is a global leading provider of proprietary capillary blood sampling and hypodermic injection devices. Global demographic megatrends, such as a growing number of insulin users and increasing need for safe point-of-care blood tests, underpin a solid underlying market growth for years to come. During EQT’s ownership, HTL-Strefa has embarked on a transformation journey from being a local manufacturer to a fully-fledged international medical device player.

Since the appointment of CEO Mikkel Danvold in January 2017 and the strengthening of HTL-Strefa’s management team, the top-line growth and earnings trajectory have been reinvigorated. The improved performance is the result of changing the commercial approach ensuring that customers and end-users are at the center of all decision-making. This approach has already led to a large number of new customers, an ongoing repositioning in the value chain, as well as implementation of multiple initiatives to ensure state-of-the-art commercial excellence and product innovation.

To meet the increased demand from both existing and new customers, HTL-Strefa is scaling up its organization and production capacity significantly. To support management in the implementation of the new expansion projects, Rick Cook will join HTL-Strefa’s Board of Directors. Rick has more than 30 years of experience in manufacturing and operations for Intravenous solutions and medical devices at all levels, from floor supervision to global operations leadership.

“As former Global Head of Operations at Becton Dickinson, Rick has a long track-record from leading large-scale projects within production and operations in the med-tech industry. Rick brings impressive experience which will be highly valuable to HTL-Strefa’s ongoing transformation. Supporting Mikkel and his team in implementing excellence in quality, service and cost from operations will bring competitive differentiation and enhanced value for customers”, says Gerard Van Odijk, Chairman of the Board of Directors at HTL-Strefa.

“I am honored to be asked to serve on HTL-Strefa’s Board of Directors. I look forward to helping Mikkel and the Operations team build upon the existing strong foundation and create a manufacturing culture and capability that will serve global customers of HTL with excellence in the exciting years ahead”, says Rick Cook, new Board Member of HTL-Strefa.

With the new commercial agenda being implemented, HTL-Strefa is uniquely positioned to further accelerate execution on the many top-line growth initiatives. The plan includes among other things a rapid channel expansion and launch of numerous new innovative products with distinct end-user benefits.

During EQT’s ownership, HTL-Strefa’s revenues have been growing at high single-digit rates and EBITDA margins have increased. With accelerated investments in product innovation and the implementation of an enhanced commercial strategy, growth has improved further to solid double-digit rates and are expected to continue to rise.

 

Categories: Personalia

Tags:

Nordic Capital invests in German healthcare operator Alloheim

Nordic Capital

Nordic Capital Fund VIII today announces its acquisition of Alloheim, the second largest private German care home operator.

Alloheim offers nationwide care services for different age groups in stationary care homes, at assisted living locations and via ambulatory services. Alloheim which was a pioneer in the German market having opened its first location in 1973, has grown to employ c. 14,500 medical professionals and staff and is home to up to 20,000 residents.

Nordic Capital is an established healthcare investor with a track record of building high quality, sustainable businesses. Nordic Capital intends to support Alloheim management’s strategy to continue to deliver high quality services and care to its residents, and to invest in further expanding the facilities and services offered by Alloheim.

The transaction is subject to customary antitrust and regulatory approvals.

 

 

Media contacts:

Katarina Janerud, Communications manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

 Nordic Capital invests in German healthcare operator Alloheim Image

About Alloheim

Alloheim is the second largest private and one of the fastest growing German nursing home operators with more than 170 stationary nursing care homes (incl. 10 new-builds under construction), 52 facilities for assisted living and 17 ambulatory care services. The group provides in total c. 20,000 beds of which 18,000 are stationary care beds and c. 2,000 apartments for assisted living. Amongst the stationary care services, the group offers a variety of specialized care including advanced dementia, youth & psychiatric care, adiposity and artificial respiration. Alloheim currently employs around 14,500 employees. Headquarter is in Duesseldorf, Germany. For further information about Alloheim please visit www.alloheim.de

About Nordic Capital

Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 11 billion through eight funds. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com

 

Categories: News

Tags: